Table 1.

Characteristics of Patients Exposed to Influenza and Prescribed Postexposure Prophylaxis With Oseltamivir for 5 or 10 Days

	ITT Analysis			PP Analysis
Characteristic	5 d (n = 110)	10 d (n = 112)	P Value	5 d (n = 102)	10 d (n = 95)	P Value
Age, y	77 (63.8–84)	73 (64–81)	.39	77 (63.8–84)	73 (64–81)	.33
Male sex	57 (51.8)	62 (55.4)	.69	53 (52.0)	52 (54.7)	.81
Charlson Comorbidity Index	5 (3–7)	5.5 (4–7)	.42	5 (3–7)	6 (4–7)	.38
Vaccinated against influenza	10 (9.1)	12 (10.7)	.86	10 (9.8)	9 (9.5)	1.00
Risk factor for complications from influenza
Age ≥65 y	82 (74.5)	82 (73.2)	.94	76 (74.5)	69 (72.6)	.89
Chronic pulmonary disorder	16 (14.5)	18 (16.1)	.90	16 (15.7)	16 (16.8)	.98
Chronic cardiovascular disorder	68 (61.8)	69 (61.6)	1.00	62 (60.8)	56 (58.9)	.91
Chronic renal disorder	18 (16.4)	20 (17.9)	.91	15 (14.7)	17 (17.9)	.68
Chronic hepatic disorder	4 (3.6)	8 (7.1)	.39	4 (3.9)	7 (7.4)	.46
Chronic neurologic disorder	30 (27.3)	27 (24.1)	.70	27 (26.5)	22 (23.2)	.71
Metabolic disorder	49 (44.5)	42 (37.5)	.35	44 (43.1)	36 (37.9)	.55
Immunosuppression	14 (12.7)	12 (10.7)	.80	12 (11.8)	11 (11.6)	1.00
Days of exposurea	2 (1–3)	2 (1–3)	<.01	2 (1–3)	2 (1–3)	<.01
Type of department						.88
Infectious diseases	32 (29.1)	35 (31.3)	.79	31 (30.4)	32 (33.7)
General medicine	63 (57.3)	65 (58.0)		58 (56.9)	52 (54.7)
Surgical	15 (13.6)	12 (10.7)		13 (12.8)	11 (11.6)
Hospitalization, d	14 (8–23.5)	15 (10–27.3)	.09	14 (8–25.5)	17 (11–29)	.05
Bedridden patients	40 (36.4)	54 (48.2)	.10	37 (36.3)	46 (48.4)	.11
Bedridden index cases	44/100 (44)	43/90 (47.8)	.71	40/92 (43.5)	33/75 (44.0)	1.00

Abbreviations: ITT, intention to treat; PP, per protocol.

^aDuration of exposure to influenza, that is, sharing a room for ≥12 hours with an index case receiving the first 3 days of oseltamivir therapy.